Save your place

Sign in to WhoBought

Please try again later.

Structure Therapeutics Inc. (GPCR) institutional ownership

Market cap$1.0B SectorHealthcare
Funds holding · Q1 2026
205
reported GPCR position changes
Top owners · Q1 2026
No disclosed owners are available.
Institutional activity · Q1 2026
Activity unavailable N/A
110 buyers · 95 sellers

Structure Therapeutics Inc. (GPCR) price and institutional activity

Dates

Q1 2026

$0 bought by 110 investors
American Century Companies IncParadigm Biocapital Advisors LP +108 more
$0 sold by 95 investors
Tcg Crossover Management, LLCCitadel Advisors LLC +93 more
Sign in to see who bought
Bought Sold Totals per quarter; hover a bar for the names.

Structure Therapeutics Inc. (GPCR) institutional activity · 205

Investor Type Est. change Change Δ Own Date
American Century Companies Inc · Added
Change +931K Date Q1 2026
American Century Companies Inc Added· Q1 2026 +931K Q1 2026
Tcg Crossover Management, LLC · Reduced
Change −780K Date Q1 2026
Tcg Crossover Management, LLC Reduced· Q1 2026 −780K Q1 2026
Citadel Advisors LLC Exited· Q1 2026 −773K −100.0% Q1 2026
Paradigm Biocapital Advisors LP · New
Change +545K Date Q1 2026
Paradigm Biocapital Advisors LP New· Q1 2026 +545K Q1 2026
Deutsche Bank AG · Reduced
Change −509K Date Q1 2026
Deutsche Bank AG Reduced· Q1 2026 −509K Q1 2026
Principal Financial Group Inc · Added
Change +470K Date Q1 2026
Principal Financial Group Inc Added· Q1 2026 +470K Q1 2026
Farallon Capital Management LLC · Exited
Change −454K Δ Own −100.0% Date Q1 2026
Farallon Capital Management LLC Exited· Q1 2026 −454K −100.0% Q1 2026
Ecor1 Capital, LLC · Exited
Change −334K Δ Own −100.0% Date Q1 2026
Ecor1 Capital, LLC Exited· Q1 2026 −334K −100.0% Q1 2026
T. Rowe Price Associates · Added
Change +330K Date Q1 2026
T. Rowe Price Associates Added· Q1 2026 +330K Q1 2026
Orbimed Advisors LLC · Added
Change +314K Date Q1 2026
Orbimed Advisors LLC Added· Q1 2026 +314K Q1 2026
FMR LLC · Reduced
Change −309K Δ Own −3.5% Date Q1 2026
FMR LLC Reduced· Q1 2026 −309K −3.5% Q1 2026
Capitolis Liquid Global Markets LLC · Added
Change +273K Date Q1 2026
Capitolis Liquid Global Markets LLC Added· Q1 2026 +273K Q1 2026
Janus Henderson Group PLC · Added
Change +265K Date Q1 2026
Janus Henderson Group PLC Added· Q1 2026 +265K Q1 2026
Capricorn Fund Managers Ltd · Exited
Change −253K Δ Own −100.0% Date Q1 2026
Capricorn Fund Managers Ltd Exited· Q1 2026 −253K −100.0% Q1 2026
Siren, L.L.C. · Added
Change +250K Date Q1 2026
Siren, L.L.C. Added· Q1 2026 +250K Q1 2026
Data through Q1 2026 · filed Jun 4, 2026
15 of 205

Famous investor activity in Structure Therapeutics Inc. (GPCR)

Structure Therapeutics Inc. (GPCR) insider trading

Company insiders, action and economics first; trade and filed dates last.
Dates
Insider Title Type Price Qty Value Owned ΔOwn Trade date Filed date
Lin Xichen · Officer 2 operations -$402K
Price $50.80–$51.71 Qty -8K Owned 0 Trade date Jul 14, 2026 Filed date Jul 15, 2026
Lin Xichen Officer 2 operations $50.80–$51.71 -8K -$402K 0 Jul 14, 2026 Jul 15, 2026
Lin Xichen · Officer 4 operations -16K
Price $0.34 Owned 8K Trade date Jul 14, 2026 Filed date Jul 15, 2026
Lin Xichen Officer 4 operations $0.34 -16K 8K Jul 14, 2026 Jul 15, 2026
Lin Xichen · Officer Other Form 4 event (S, derivative) -$387K
Price $49.08 Qty -8K Owned 0 Trade date Jun 25, 2026 Filed date Jun 29, 2026
Lin Xichen Officer Other Form 4 event (S, derivative) $49.08 -8K -$387K 0 Jun 25, 2026 Jun 29, 2026
Lin Xichen · Officer 4 operations -16K
Price $0.34 Owned 8K Trade date Jun 25, 2026 Filed date Jun 29, 2026
Lin Xichen Officer 4 operations $0.34 -16K 8K Jun 25, 2026 Jun 29, 2026
Russell Angus C. · Director Grant (A) 39K
Owned 39K Trade date Jun 17, 2026 Filed date Jun 18, 2026
Russell Angus C. Director Grant (A) 39K 39K Jun 17, 2026 Jun 18, 2026
Love Ted W. · Director Grant (A) 39K
Owned 39K Trade date Jun 17, 2026 Filed date Jun 18, 2026
Love Ted W. Director Grant (A) 39K 39K Jun 17, 2026 Jun 18, 2026
Waldstreicher Joanne · Director Grant (A) 39K
Owned 39K Trade date Jun 17, 2026 Filed date Jun 18, 2026
Waldstreicher Joanne Director Grant (A) 39K 39K Jun 17, 2026 Jun 18, 2026
Dobmeier Eric · Director Grant (A) 39K
Owned 39K Trade date Jun 17, 2026 Filed date Jun 18, 2026
Dobmeier Eric Director Grant (A) 39K 39K Jun 17, 2026 Jun 18, 2026
Tetlow Sharon · Director Grant (A) 39K
Owned 39K Trade date Jun 17, 2026 Filed date Jun 18, 2026
Tetlow Sharon Director Grant (A) 39K 39K Jun 17, 2026 Jun 18, 2026
Welch Daniel G. · Director Grant (A) 39K
Owned 39K Trade date Jun 17, 2026 Filed date Jun 18, 2026
Welch Daniel G. Director Grant (A) 39K 39K Jun 17, 2026 Jun 18, 2026
Lang Matthew · Officer 2 operations 408K
Owned 224K Trade date Apr 15, 2026 Filed date Apr 23, 2026
Lang Matthew Officer 2 operations 408K 224K Apr 15, 2026 Apr 23, 2026
FMR LLC · 10% Owner 2 operations -$961K
Price $55.07 Qty -17K Owned 32K Trade date Apr 14, 2026 Filed date Apr 16, 2026
FMR LLC 10% Owner 2 operations $55.07 -17K -$961K 32K Apr 14, 2026 Apr 16, 2026
Hall Ashley · Officer 2 operations 107K
Owned 59K Trade date Mar 19, 2026 Filed date Mar 23, 2026
Hall Ashley Officer 2 operations 107K 59K Mar 19, 2026 Mar 23, 2026
Coll Crespo Blas · Officer 2 operations 170K
Owned 94K Trade date Mar 19, 2026 Filed date Mar 23, 2026
Coll Crespo Blas Officer 2 operations 170K 94K Mar 19, 2026 Mar 23, 2026
Ma Yingli · Officer 2 operations 73K
Owned 40K Trade date Mar 19, 2026 Filed date Mar 23, 2026
Ma Yingli Officer 2 operations 73K 40K Mar 19, 2026 Mar 23, 2026
15 of 24
15 of 24 Sign in to continue to older insider transactions.

Structure Therapeutics Inc. (GPCR) activist and large shareholders

What are Schedules 13D and 13G?

Dates
Owner/Filer identity Shares reported % of shares outstanding Filing date
Biotechnology Value Fund L P 1.3M
% of shares outstanding 12822540.0% Filing date Dec 20, 2023
Biotechnology Value Fund L P 1.3M 12822540.0% Dec 20, 2023
FMR LLC 23.6M
% of shares outstanding 15.0% Filing date Nov 12, 2024
FMR LLC 23.6M 15.0% Nov 12, 2024
Wellington Management Group LLP 23.3M
% of shares outstanding 13.9% Filing date Nov 8, 2024
Wellington Management Group LLP 23.3M 13.9% Nov 8, 2024
Janus Henderson Group PLC 4.0M
% of shares outstanding 6.9% Filing date Nov 14, 2024
Janus Henderson Group PLC 4.0M 6.9% Nov 14, 2024
Capital Research Global Investors 10.6M
% of shares outstanding 6.2% Filing date Nov 12, 2024
Capital Research Global Investors 10.6M 6.2% Nov 12, 2024
Ra Capital Management, L.P. 5.7M
% of shares outstanding 3.3% Filing date Nov 14, 2024
Ra Capital Management, L.P. 5.7M 3.3% Nov 14, 2024
Deep Track Capital, LP
% of shares outstanding 0.7% Filing date Feb 14, 2024
Deep Track Capital, LP 0.7% Feb 14, 2024
Fil Ltd 28K
% of shares outstanding 0.0% Filing date Feb 9, 2024
Fil Ltd 28K 0.0% Feb 9, 2024
8 of 9

Structure Therapeutics Inc. (GPCR) ownership FAQ

Who owns GPCR?

205 reporting institutions disclosed GPCR position changes in the Q1 2026 snapshot.

How is institutional activity calculated?

For each manager, WhoBought compares accepted consecutive 13F share counts. Share change is current shares minus prior shares. Estimated dollar change is that signed share change multiplied by the split-adjusted quarter-mean close. The activity table on this page uses Q1 2026.

What are activist and large shareholder filings?

An investor crossing 5% of a share class generally files Schedule 13D for activist intent or Schedule 13G for a passive position. The technical form names appear here rather than in the activity rows.

Where does this data come from?

Ownership and institutional activity come from SEC Form 13F filings. Insider activity comes from SEC Form 4, and large-shareholder activity from SEC Schedules 13D and 13G. FMP supplies price data only. Company logos use the local verified Parqet cache with one shared fallback.

Why are ownership reports delayed?

Form 13F is a quarterly disclosure and is normally filed after the quarter ends. Every ownership and activity value therefore names its represented period; it is not presented as a live position.

How are missing table values shown?

A muted dash marks a missing table value. It means the filing omitted the value, comparable data is unavailable, or no prior position exists for comparison.